Research Links Artificial Sweeteners to Cancer Treatment Effectiveness
Recent studies suggest that common artificial sweeteners might hinder cancer treatments. Specifically, sucralose—often found in diet sodas and low-calorie snacks—has been shown to potentially interfere with immunotherapy in cancer patients, according to research conducted by the University of Pittsburgh and the UPMC Hillman Cancer Center.
The study assessed 132 patients suffering from melanoma, a serious type of skin cancer, and non-small cell lung cancer, the most prevalent lung cancer. All participants were undergoing anti-PD1 immunotherapy, either alone or combined with chemotherapy. They also completed a Nutritional Disorders Survey to gauge their intake of artificial sweeteners.
The findings indicated that those consuming higher amounts of sucralose reported poorer responses to immunotherapy and exhibited lower survival rates. Diwakar Daval, an Associate Professor at the University of Pittsburgh and a medical oncologist at UPMC, noted the concerning health issues that many patients face in such treatments.
Interestingly, the researchers suggested that tailored nutrition plans could help those who consume high levels of sucralose. Their work has been documented in the journal Cancer Discovery.
While it’s fairly easy to suggest cutting out diet sodas, the reality is often more complex. Patients undergoing cancer treatment have already faced considerable challenges, so asking them to drastically change their diets might not be practical, said Abby Oberaar, an assistant professor at UPMC Hillman Cancer Center.
The research also highlighted a glimmer of hope. Supplementation with the amino acid arginine seemed to counteract the adverse effects of sucralose, enhancing the efficacy of immunotherapy in mouse models. This could, perhaps, be a relatively straightforward method to help patients who may still want to enjoy their favorite beverages.
Daval emphasized that when patients start consuming sucralose, it might cause shifts in their gut microbiota that could lower arginine levels, which are crucial for T-cell function. If these levels drop, then the immunotherapy’s effectiveness diminishes.
Looking ahead, researchers plan to initiate clinical trials focused on the implications of arginine supplementation for human patients. They’re also keen to explore how different sugar substitutes impact the success of immunotherapy.
This study received backing from various organizations, including the National Institutes of Health and the Damon Lannion Cancer Research Foundation. Carla Sanders, president of the Calorie Control Council, stressed the importance of consulting with medical teams for guidance on nutrition during cancer treatments.
It’s essential to remember that while studies like this provide valuable insights, they also have limitations. Much of the existing research, as noted, cannot be directly applied to humans, thus underscoring the need for continued investigation into this critical area of health.
